Wisconsin is currently home to 1287 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: University of Wisconsin Carbone Cancer Center (UWCCC) - 1612, Madison, Wisconsin
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
NCT04973137
Recruiting
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
Long-term Follow-up Study of Patients Receiving CAR-T Cells
NCT03375619
Recruiting
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT0509... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/30/2024
Locations: Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma
Register for Updates
Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery
NCT06213454
Recruiting
This study is being done to see if preoperative transversus abdominis plane (TAP) analgesia will provide similar postoperative pain control, hospital length of stay, and postoperative outcomes compared to surgeon-initiated wound infiltration with local anesthetic in participants undergoing laparotomy for gynecologic indications.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Wisconsin Hospitals and Clinics (UWHC), Madison, Wisconsin
Conditions: Analgesia, Surgery
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
XTX301 in Patients with Advanced Solid Tumors
NCT05684965
Recruiting
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Advanced Solid Tumor
Register for Updates
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT04762979
Recruiting
Patients who have histologically confirmed metastatic or unresectable (not amenable to curative therapy) breast cancer may be screened for eligibility. All patients must have HER2 negative breast cancer with the identified PIK3CA mutation and received at least one line of endocrine therapy. The study will consist of a screening phase, a treatment phase, and a post-treatment phase which includes safety, efficacy, and follow-up. The treatment phase will include taking alpelisib daily in combinatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Register for Updates
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
10/28/2024
Locations: Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Register for Updates
Clinical Decision Support Tool in PARDS Pilot Study
NCT04068012
Recruiting
Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS). This will be accomplished by using CDS t... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
10/28/2024
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Ventilation Therapy; Complications, Ventilator-Induced Lung Injury, Ards
Register for Updates
Cognitive Behavioral and Faith Fellowship to Improve Thy Health
NCT06292637
Recruiting
Investigators will examine the efficacy of a faith-based depression intervention, in reducing symptoms of depression among African American adults in Wisconsin. Twelve church groups, each with 10 people (N=120) will be invited to participate. This intervention will be the first evidence-based, faith-based intervention designed for African Americans if validated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Second Baptist Church, Madison, Wisconsin
Conditions: Depression
Register for Updates
Study of 18F-FFNP Breast PET/MRI
NCT06086704
Recruiting
This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine the quantitative reliability of 18F-FFNP breast PET/MRI in patients with newly diagnosed PR+ primary breast c... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: UW Carbone Cancer Center, Madison, Wisconsin
Conditions: Breast Cancer
Register for Updates
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
NCT05980416
Recruiting
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: UW Carbone Cancer Center - Cancer Connect, Madison, Wisconsin
Conditions: Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
Register for Updates